Dr. Fauci had little reason to worry that insiders would complain about the corruption of the study, since his trusted deputy, Cliff Lane, chaired the NIH Treatment Guidelines panel.40 Lane was doubly conflicted, since he had personally overseen the remdesivir trials in China, and stood, potentially, to share in patent rewards and royalties for the drug.41 In addition to Lane, seven of the panel members had financial relationships with Gilead—and eight additional panel members had had financial relationships with Gilead prior to the past eleven months, for which they were required to declare a
...more
